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ABSTRACT
Background Restless legs syndrome (RLS) is a sleep
related movement disorder that occurs both in an
idiopathic form and in symptomatic varieties. RLS is
a frequent and distressing comorbidity in end stage renal
disease (ESRD). For idiopathic RLS (iRLS), genetic risk
factors have been identiﬁed, but their role in RLS in ESRD
has not been investigated yet. Therefore, a caseecontrol
association study of these variants in ESRD patients was
performed.
Methods The study genotyped 10 iRLS associated
variants at four loci encompassing the genes MEIS1,
BTBD9, MAP2K5/SKOR1, and PTPRD, in two
independent caseecontrol samples from Germany and
Greece using multiplex PCR and MALDI-TOF (matrix
assisted laser desorption/ionisation time-of-ﬂight) mass
spectrometry. Statistical analysis was performed as
logistic regression with age and gender as covariates.
For the combined analysis a CochraneManteleHaenszel
test was applied.
Results The study included 200 RLS-positive and 443
RLS-negative ESRD patients in the German sample, and
141 and 393 patients, respectively, in the Greek sample.
In the German sample, variants in MEIS1 and BTBD9
were associated with RLS in ESRD (Pnom#0.004, ORs
1.52 and 1.55), whereas, in the Greek sample, there was
a trend for association to MAP2K5/SKOR1 and BTBD9
(Pnom#0.08, ORs 1.41 and 1.33). In the combined
analysis including all samples, BTBD9 was associated
after correction for multiple testing (Pcorrected¼0.0013,
OR 1.47).
Conclusions This is the ﬁrst demonstration of a genetic
inﬂuence on RLS in ESRD patients with BTBD9 being
signiﬁcantly associated. The extent of the genetic
predisposition could vary between different subgroups of
RLS in ESRD.
INTRODUCTION
Restless legs syndrome (RLS) in end stage renal
disease (ESRD) is a common form of symptomatic
RLS and is associated with increased mortality and
reduced quality of life.
1 The prevalence of RLS
ranges between 18.4%
2 and 45.8%
3 in ESRD
patients of European descent. Both RLS in ESRD
and idiopathic RLS (iRLS) are diagnosed based on
the clinical presentation of four main symptoms.
These are speciﬁed in the essential diagnostic
criteria deﬁned by the International RLS Study
Group (IRLSSG)
4: (1) an urge to move the legs,
usually accompanied by unpleasant sensations; (2)
precipitation of symptoms by rest and inactivity;
(3) symptom relief by movement; and (4) wors-
ening appearance in the evening or at night. An
abnormal increase in periodic limb movements in
sleep (PLMS) further supports the diagnosis and is
present in 80e89% of RLS patients.
5
For iRLS, a relatively strong genetic contribution
has been demonstrated.
6 Genome-wide association
studies (GWAS) in iRLS cases from Germany and
Iceland identiﬁed variants at four loci encompassing
the genes MEIS1, BTBD9, MAP2K5/SKOR1, and
PTPRD.
7e9 Replication studies in iRLS cases from
the USA and Europe (Czech Republic, Austria, and
Finland) conﬁrmed the association of MEIS1 and
BTBD9. The MAP2K5/SKOR1 locus was replicated
in the European cases but showed only a trend for
association in the US cases.
10 11 With regard to
ESRD, association studies have identiﬁed more
than 20 variants contributing to disease suscepti-
bility.
12 There is no overlap between these variants
and the known iRLS associated variants.
The pathophysiology of RLS in ESRD remains
to be elucidated. So far, comparing clinical and
biochemical parameters, such as duration and
frequency of dialysis treatment or various compo-
nents of phosphate and iron metabolism, in RLS-
positive and RLS-negative ESRD patients yielded
ambiguous results.
3 13e18
If and to what extent the susceptibility to RLS in
ESRD is inﬂuenced by a genetic predisposition is
not known. Since RLS in ESRD and iRLS are
characterised by the same key symptoms, they
possibly share genetic risk factors. Accordingly, we
investigated the iRLS associated variants
7e9 in
a caseecontrol association study of ESRD patients
from Germany and Greece.
SUBJECTS AND METHODS
Study populations and recruitment procedures
Germany (GER)
ESRD patients on maintenance haemodialysis were
recruited between January 2005 and August 2008 in
16 dialysis centres in Munich and the surrounding
region.
ESRD patients who agreed to participate in the
study answered a self administered diagnostic
For numbered afﬁliations see
end of article.
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Complex traitsquestionnaire incorporating the four essential IRLSSG criteria.
4 19
All patients who answered at least one question afﬁrmatively
were then examined by a clinician specialising in RLS (JP or NG)
by face-to-face interview and classiﬁed as ‘RLS-positive’ or ‘RLS-
uncertain’ (if less than four diagnostic criteria were fulﬁlled)
according to this interview. Patients who had answered all
diagnostic questions negatively in the initial questionnaire were
classiﬁed as ‘RLS-negative’ without a personal interview.
Greece (GR)
ESRD patients on maintenance haemodialysis were recruited
between January 2007 and December 2009 in seven dialysis
centres in central and northern Greece. In brief, patients were
interviewed (ﬁrst screening), using the four IRLSSG criteria, by
a nephrologist (AV) or neurologist (ED) trained by RLS experts
(GMH and IS).
4 20 The diagnosis of RLS was conﬁrmed in
a subsequent personal interview conducted by an expert
neurologist (GMH or IS).
In both populations, family history of RLS (deﬁned as the
proband’s report of at least one relative of up to the third degree
affected by RLS) was recorded for RLS-positive patients. Data on
duration of dependence on dialysis and on weekly rate of dialysis
was collected for all ESRD patients. In the German sample, age
of onset of RLS was also recorded.
The study was approved by the respective local ethics
committees in Germany and Greece. All patients were informed
about the aims and protocol of the study. Written informed
consent was obtained from all patients.
SNP selection, genotyping, and quality control
We genotyped 10 iRLS associated single nucleotide poly-
morphisms (SNPs) across the four genomic regions.
7e9 Geno-
typing was performed according to the iPLEX Gold protocol
using matrix assisted laser desorption/ionisation time-of-ﬂight
(MALDI-TOF) mass spectrometry (Sequenom, San Diego,
California, USA). Assays were designed using AssayDesign
3.1.2.2 with the default parameters for the iPLEX Gold chem-
istry. Cleaned extension products were analysed by mass spec-
trometer (Bruker Daltronik, Bremen, Germany) and peaks were
identiﬁed using SpectroTYPER RT 3.4.
Quality control criteria leading to exclusion of an SNP from
further analysis were a call rate <95%, a minor allele frequency
(MAF) <5%, and value of p<0.001 for deviation from
HardyeWeinbergeEquilibrium (HWE) in controls. Furthermore,
DNA samples with a call rate <95% over all SNPs were excluded
from the analysis.
Statistical analysis
Statistical analysis was performed using PLINK v1.07
21 for the
SNP association tests and R 2.10.1 (http://www.r-project.org) for
all other analyses. Statistical signiﬁcance was deﬁned at the 95%
level (p<0.05). Association of disease status and SNP allele count
was tested using logistic regression, with age and gender as
covariates. For the combined analysis of both populations, the
sample was stratiﬁed based on the country of origin and
aC o c h r a n eManteleHaenszel test was applied. To correct for
multiple testing, empirical p values were generated by the max (T)
permutation procedure implemented in PLINK v1.07 (n¼10000).
Dialysis parameters and mean age were compared between
cases and controls by means of a two-sided Student’s t test. A c
2
test was utilised to compare gender ratios. Study power was
calculated using the CATs power calculator,
22 with settings of an
additive genetic model, disease prevalence of 0.2, and risk allele
frequencies and ORs as estimated in previous studies.
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RESULTS
Study populations
In the German study, 737 of 1617 ESRD patients agreed to
participate (45.6%). Many ESRD patients had comorbidities
such as dementia or depression and were not able to participate,
leading to the relatively low response rate. According to the
diagnostic questionnaire, 253 ESRD patients were considered
‘potential RLS in ESRD’ cases. Of these, 53 were subsequently
excluded from the study (uncertain diagnosis: n¼44; non-Euro-
pean descent: n¼6; incomplete data: n¼3). The ﬁnal study
population included 200 RLS-positive patients (prevalence of
RLS in ESRD 31.1%). Positive family history of RLS was
reported by 38 of these patients (19%), 133 (66.5%) had a nega-
tive family history, and for 29 (14.5%) there was no information
available. Controls were selected from 484 RLS-negative ESRD
patients. Of these, 41 were excluded from the study (non-
European descent: n¼13, incomplete data: n¼28), yielding
a ﬁnal control sample of 443 RLS-negative ESRD patients. Cases
and controls did not differ signiﬁcantly with regard to age,
gender ratio, and the recorded dialysis parameters (table 1).
In the Greek study, 572 of 613 ESRD patients agreed to
participate (93.3%). According to the ﬁrst screening, 162 ESRD
patients were considered ‘potential RLS in ESRD’ cases. Of
these, 21 were subsequently excluded from the study (uncertain
diagnosis: n¼15; non-European descent: n¼1; incomplete data:
n¼5), resulting in a case sample of 141 RLS-positive patients
(prevalence of RLS in ESRD 26.4%). Positive family history of
RLS was reported by seven patients (4.9%), 129 (91.5%) had
a negative family history, and for ﬁve (3.6%) no information was
available. Controls were selected from 410 RLS-negative ESRD
patients. After excluding 17 patients due to incomplete data, 393
RLS-negative ESRD patients remained. Cases and controls had
a signiﬁcantly different mean age, but were similar in gender
ratio and dialysis parameters (table 1).
Table 1 Demographic and dialysis data of ﬁnal study population
GER GR GER vs GR
RLS-positive ESRD
patients n[200
RLS-negative ESRD
patients n[443 p Value
RLS-positive ESRD
patients n[141
RLS-negative ESRD
patients n[393 p Value p Value
Mean dialysis duration
(hours per week, mean6SD)
13.662.2
(NA for 42 patients)
13.662.7
(NA for 138 patients)
0.81 12.060.3 11.960.4 0.31 2.2310
 10
Mean dependence on dialysis
(months, mean6SD)
70.7668.5
(NA for 34 patients)
60.7662.2
(NA for 105 patients)
0.11 45.2641 41.6645.8 0.9 8.1310
 10
Age (years, mean6SD) 64.8612.5 65613.4 0.9 60.3612.4 66613.4 5.4310
 6 0.58
Gender (% female) 56.5 64.1 0.07 56.7 61.3 0.34 0.57
Age of onset of RLS
(years, mean6SD)
54.8615.4
(NA for 51 patients)
ee NA ee e
Age and dialysis parameters were analysed by two-sided Student’s t tests. Gender ratios were subjected to a c
2 test.
GER, German; GR, Greek; n, number; NA, not available; e, not applicable.
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Complex traitsComparison of demographic data and dialysis parameters
between the German and the Greek sample showed signiﬁcant
differences in the weekly rate of dialysis and the mean duration
of dependence on dialysis, whereas mean age and gender ratios
were similar (table 1).
Association analysis
The 10 selected SNPs passed quality control and were subjected
to statistical analysis. A total of 43 individuals (22 in GER
sample, 21 in GR sample) were excluded due to low genotyping
quality. Analysis of the German sample (195 cases and 426
controls) revealed signiﬁcant association to RLS in ESRD for
variants in MEIS1 and BTBD9 (table 2). Within MEIS1, two of
three SNPs were signiﬁcantly associated after correction for
multiple testing: rs12469063 (Pnom¼0.002, Pcorrected¼0.013, OR
1.52) and rs2300478 (Pnom¼0.004, Pcorrected¼0.026, OR 1.47). In
BTBD9, rs3923809 was associated (Pnom¼0.001, Pcorrected¼0.009,
OR 1.56). For MAP2K5/SKOR1 and PTPRD the nominal p values
ranged from 0.17 to 0.69 (table 2). In contrast, the Greek sample
(138 cases, 375 controls) showed only nominal signiﬁcance for
a single SNP in MAP2K5/SKOR1 (rs3784709, Pnom¼0.021) and
a trend of association for two further SNPs in MAP2K5/SKOR1
and for rs3923809 in BTBD9 (table 2). In the combined analysis
of all samples, stratiﬁed according to the country of origin,
rs3923809 in BTBD9 and four SNPs in MAP2K5/SKOR1 showed
nominal signiﬁcance, but only rs3923809 remained signiﬁcant
after correction for multiple testing (table 2).
The statistical power of the German sample was higher than
that of the Greek sample, owing to the larger sample size. For
MEIS1, power in both samples was $90%, for BTBD9 it was
85% in the German sample and 74% in the Greek sample. For the
other loci, power was <80% in both populations (table 2).
A subanalysis in the German sample with cases stratiﬁed
accordingtotheirfamilyhistoryrevealedatrendfordifferencesin
thesizeofthecontributionoftheassociatedlocitofamilialversus
sporadic RLS in ESRD. Analysis of cases with a positive family
history only (n=38) revealed a signiﬁcant association both with
MEIS1 and BTBD9 (rs12469063, Pnom¼0.003, Pcorrected¼0.014;
rs2300478, Pnom¼0.005, Pcorrected¼0.023, and rs3923809,
Pnom¼0.006, Pcorrected¼0.03). Using only cases with a negative
family history (n¼133), the two loci showed nominally signiﬁ-
cant p values (rs12469063, Pnom¼0.038, Pcorrected¼0.224;
rs2300478, Pnom¼0.055, Pcorrected¼0.306, and rs3923809,
Pnom¼0.025, Pcorrected¼0.147). ORs differed for both groups but
the 95% CIs overlapped: positive family history: MEIS1: 2.1
(1.29e3.39); BTBD9: OR 2.39 (95% CI 1.28 to 1.87); negative
familyhistory:MEIS1:OR1.38(95%CI1.02to1.87);BTBD9:OR
1.42 (95% CI 1.05 to 1.92). The Greek sample did not contain
enough cases with a positive family history (n¼7) to conduct
a similar analysis.
DISCUSSION
It has long been known that idiopathic and symptomatic RLS
share the same key symptoms and that iRLS susceptibility is
subject to genetic inﬂuences. Here, we show that genetic
predisposition also plays a role in RLS in ESRD and that at least
some of the underlying risk variants are common to both iRLS
and RLS in ESRD.
In the German sample, sequence variants in MEIS1 and
BTBD9 were clearly identiﬁed as genetic susceptibility factors for
RLS in ESRD patients (Pcorrected ≤ 0.03). The effect size of these
variants is within the same range as observed in iRLS studies of
comparable sample size (ORsRLS in ESRD 1.47e1.55, 95% CI 1.19
to 2.04; ORsiRLS 1.43e1.59, 95% CI 1.12 to 2.2).
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Complex traitsconﬁrmed in an analysis using population based controls as the
control group yielding similar ORs and CIs for the associated
genes MEIS1 and BTBD9 (data not shown). However, the
present data did not indicate a contribution of variants in
MAP2K5/SKOR1 and PTPRD to RLS in ESRD in the German
sample. The absence of signiﬁcant association to these loci may
be due to the relatively small sample sizes in our studydthat is,
to the limited power.
Concerning the Greek sample, we could observe a trend for
association to BTBD9 and MAP2K5/SKOR1. Several differences
between both samples could account for the divergences
between the German and the Greek results. (1) Sample sizes
differed. (2) Greek ESRD patients were on dialysis for a signiﬁ-
cantly shorter time than the German patients and at a lower
weekly rate (table 1). In several previous studies, the frequency
of RLS in ESRD increased with the duration of dependence on
dialysis.
3 13e18 It is possible, therefore, that some of the currently
RLS-negative Greek ESRD patients will develop RLS in the
future. Such false-negative controls would distort the association
results. (3) The samples differed notably in the percentage of
RLS cases with a positive family history (19% in GER vs 5% in
GR). The subanalysis based on family history of RLS in the
German sample suggested a stronger contribution of the genetic
risk factors in cases with a positive family history. This trend has
also been observed in iRLS populations.
10 11 The lower
percentage of familial RLS could thus explain the weakened
association signal for BTBD9 in the Greek sample. However, it
has to be considered that the information on family history was
obtained only by the proband’s report, and was not conﬁrmed in
a direct personal interview of the relatives. Therefore, both false-
negative and false-positive classiﬁcations may have occurred. (4)
For MEIS1, we see a sizeable difference in allele frequency
between Greek and German RLS-positive ESRD patients
(table 2), indicating that in the Greek population either MEIS1 is
not an RLS risk factor or the causal variant in MEIS1 may not be
in linkage disequilibrium with the variants under study.
Despite the differences in sample characteristics and indi-
vidual association results, BTBD9 shows a consistent trend for
association in the separate as well as the combined samples.
Previous analysis in iRLS has linked BTBD9 to the presence of
PLMS, the motor component of RLS.
9 Therefore, its association
with RLS in ESRD is remarkable because motor symptoms seem
to be more prominent in RLS in ESRD when compared to
iRLS.
23 24
The prevalence of RLS in ESRD observed in our study (31.1%
in GER, 26.4% in GR) is in keeping with previous investiga-
tions,
2 14e18 and higher than that of RLS in the general popu-
lation at the same age (10% in GER, 3.9% in GR).
20 25 26 The
prevalence of iRLS is substantially lower in Greece, while the
prevalence of ESRD is quite similar with prevalence rates of
0.11% and 0.10% in Germany and Greece, respectively.
27
The effect sizes of MEIS1 and BTBD9 in our study are of the
same magnitude as in iRLS and, thus, do not account for the
increased frequency of RLS in ESRD patients. It is likely that
there are as yet undiscovered genetic, non-genetic, or non-shared
environmental factors inﬂuencing the RLS phenotype. Our
ﬁnding that only 5% (GR) to 19% (GER) of patients with RLS in
ESRD reported a positive family history is in line with previous
observations showing a lower frequency of familial RLS (12%)
28
in cases with RLS in ESRD compared to iRLS cases (30e92%).
6
The reduced familial clustering of RLS in ESRD patients could be
interpreted as an indicator of a stronger inﬂuence of non-genetic
factors in the aetiology of RLS in ESRD as compared to iRLS.
Moreover, studies have shown that RLS symptoms are reduced
after renal transplantation,
29 suggesting that non-genetic factors
such as reduced renal function and incomplete clearance of
uraemic toxins during dialysis could have a major inﬂuence on
the development of RLS in ESRD.
In conclusion, we were able to show a genetic contribution to
susceptibility for RLS in ESRD. BTBD9 is signiﬁcantly associated
with RLS in ESRD. Our results suggest that the genetic
inﬂuence might be stronger in the subgroup of RLS in ESRD
patients with a positive family history. The study was limited to
a subset of genes previously identiﬁed to be associated with
iRLS. A GWAS using RLS-positive (cases) and RLS-negative
(controls) ESRD patients might disclose further genetic risk
variants for RLS in ESRD. All or some of these coulddalbeit not
necessarilydalso play a role in iRLS.
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